In this task, you are given a text of many news articles seperated by special token "|||||". Your task is to summarize them.

This 1975 microscope image made available by the Centers for Disease Control and Prevention shows a cluster of smallpox viruses. (Photo: Fred Murphy, AP) 
  
 The Food and Drug Administration has approved the first drug for treating smallpox, a response to experts' fears that the virus could be used as a bioweapon. 
  
 TPOXX, or tecovirimat, is taken orally to treat smallpox "to mitigate the impact of a potential outbreak," pharmaceutical company SIGA Technologies said in a statement. 
  
 The World Health Organization declared smallpox eradicated in 1980, and vaccination for Americans against the virus was stopped, according to the Centers for Disease Control and Prevention. 
  
 The approval of the drug addresses concerns the smallpox virus could be used in biological warfare. 
  
 "This new treatment affords us an additional option should smallpox ever be used as a bioweapon," FDA Commissioner Scott Gottlieb, M.D, said in a statement. 
  
 There exists "no immediate, direct threat of a bioterrorist attack using smallpox," according to the CDC. 
  
 Researchers tested the drug's effectiveness against smallpox through studies involving animals infected with the virus. The drug was also tested with human volunteers not infected with smallpox. 
  
 Headache, nausea, and abdominal pain remained the commonly reported side effects. 
  
 The virus spread largely through direct contact with people, said the FDA. Symptoms usually appeared 10 to 14 days after infection. They included fever, exhaustion, headache and backache, as well as a rash initially consisting of small, pink bumps progressing to pus-filled sores. 
  
 Follow Brett Molina on Twitter: @brettmolina23. 
  
 Read or Share this story: https://usat.ly/2uowwCa ||||| This undated photo provided by SIGA in July 2018 shows capsules of the drug TPOXX. On Friday, July 13, 2018, U.S. regulators announced the approval of the first treatment for smallpox _ a deadly disease... (Associated Press) 
  
 This undated photo provided by SIGA in July 2018 shows capsules of the drug TPOXX. On Friday, July 13, 2018, U.S. regulators announced the approval of the first treatment for smallpox _ a deadly disease that was wiped out four decades ago _ in case the virus is used in a terror attack. (SIGA via AP) (Associated Press) 
  
 U.S. regulators Friday approved the first treatment for smallpox — a deadly disease that was wiped out four decades ago — in case the virus is used in a terror attack. 
  
 Smallpox, which is highly contagious, was eradicated worldwide by 1980 after a huge vaccination campaign. 
  
 But people born since then haven't been vaccinated, and small samples of the smallpox virus were saved for research purposes, leaving the possibility it could be used as a biological weapon. 
  
 Maker SIGA Technologies of New York has already delivered 2 million treatments that will be stockpiled by the government, which partially paid for the development of the drug, called TPOXX. 
  
 To test the drug's effectiveness, monkeys and rabbits were infected with a similar virus and then given the drug. More than 90 percent survived, the company said. Its safety was tested in several hundred healthy volunteers, who were not infected with smallpox. 
  
 Smallpox killed about 300 million people worldwide in the 20th century before its eradication. Symptoms include fever, fatigue and pus-filled sores. Until now, doctors could only provide supportive care such as IV fluids and fever remedies and isolate the patients. Vaccination can be used to prevent infection but it must be done within five days of exposure to the virus, well before symptoms appear. 
  
 "This new treatment affords us an additional option should smallpox ever be used as a bioweapon," Dr. Scott Gottlieb, head of the Food and Drug Administration, said in a statement. 
  
 The drug is a capsule, taken twice daily for 14 days. 
  
 SIGA develops vaccines and medicines for biological, chemical, radiological and nuclear attacks. Chief Executive Phil Gomez said the company is developing an IV version and is exploring selling the drug to other countries and developing it to treat other infectious diseases, including monkeypox, which African monkeys can transmit to humans. Monkeypox can then spread among people, and has a mortality rate of about 15 percent. 
  
 ___ 
  
 Follow Linda A. Johnson at https://twitter.com/LindaJ_onPharma 
  
 ___ 
  
 The Associated Press Health & Science Department receives support from the Howard Hughes Medical Institute's Department of Science Education. The AP is solely responsible for all content. |||||
The FDA has approved a drug that could be used in the event that someone turns the deadly smallpox virus into a weapon. Per USA Today, the anti-viral tecovirimat, or TPOXX, from the pharmaceutical maker SIGA Technologies, has been given the go-ahead by the regulator to become "an additional option should smallpox ever be used as a bioweapon." The AP reports that the US government partially paid for the development of the drug, which will now be stockpiled. The drug was found to be effective against smallpox in animals infected with the virus and was found safe for use in human test subjects, who were not infected. The CDC was quick to assure the public that, despite the new drug to fight it, there is no immediate threat of the virus being used to intentionally kill. "Today's action reflects the FDA's commitment to ensuring that the US is prepared for any public health emergency with timely, safe, and effective medical products," Dr. Scott Gottlieb, head of the Food and Drug Administration, said in a statement. Smallpox is estimated to have killed some 300 million people in the 20th century. While it was eradicated by a massive vaccination effort that was deemed successful worldwide in 1980, no drug has previously been developed to fight the disease in those already infected.